Valuation benefits of structure- enabled drug discovery

  • Borshell N
  • Congreve M
  • 24


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Valuations of projects in the pharmaceutical industry rely heavily on discounted cash flow methodology, using decision-tree analysis to account for the high attrition rates at each stage of the pipeline — particularly in transitions between clinical trial phases. Increasingly, useful data are becoming available for these attrition rates, which take into account molecule type, originality, therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Nigel Borshell

  • Miles Congreve

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free